Myriad wins UPC ruling as GXD-Bio breast cancer patent is revoked
The Unified Patent Court revoked GXD-Bio’s breast cancer testing patent, rejecting infringement claims against Myriad’s EndoPredict breat cancer test and clearing the way for continued European marketing after finding added subject...To view the full article, register now.
Already a subscriber? Click here to view full article